MTM(SH:688029)2023-10-27 16:00Financial Performance - In Q3 2023, the company achieved a revenue of RMB 598.19 million, representing a year-on-year growth of 8.41%[17] - The net profit attributable to shareholders reached RMB 122.23 million, an increase of 19.70% compared to the same period last year[17] - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 118.77 million, up 22.29% year-on-year[17] - For the first three quarters of 2023, the company reported a total revenue of RMB 1.75 billion, a 15.42% increase from RMB 1.51 billion in the same period last year[19] - The net profit attributable to shareholders for the first three quarters was RMB 386.53 million, reflecting a significant growth of 70.31% year-on-year[19] - The diluted earnings per share for the quarter were RMB 0.6504, a 70.74% increase compared to the same period last year[8] - Operating profit for the first three quarters of 2023 was approximately $457.82 million, compared to $276.32 million in the previous year, indicating an increase of about 65.6%[33] - Net profit for the first three quarters of 2023 was approximately $395.08 million, a significant rise from $233.80 million in the same period of 2022, reflecting an increase of about 69%[33] - The total comprehensive income for the first three quarters of 2023 was approximately $396.00 million, compared to $234.08 million in the previous year, marking an increase of about 69.1%[34] Research and Development - Research and development expenses totaled RMB 33.93 million in Q3 2023, accounting for 5.67% of operating revenue, a decrease of 1.20 percentage points from the previous year[8] - Research and development expenses decreased to approximately $102.60 million in 2023 from $121.70 million in 2022, a reduction of about 15.7%[32] - The company launched several new products, including the NapoleonTM Endoscopic Polyp Measurement Device and Ensure Single-use Coagulation Forceps in Argentina, received certification in July 2023[36] - New product certifications in the U.S. included various biopsy forceps and stents, with certifications received in July and August 2023[38] - The company is actively expanding its product registration in both domestic and international markets[28] - The company is expanding its market presence with new product launches in multiple countries, including Germany and Brazil, throughout 2023[38] Assets and Liabilities - The company's total assets at the end of the reporting period were RMB 4.19 billion, up 7.59% from RMB 3.89 billion at the end of the previous year[8] - As of September 30, 2023, total assets increased to CNY 4,189,719,391.61 from CNY 3,894,020,049.96 as of December 31, 2022, representing a growth of approximately 7.6%[40] - Current assets rose to CNY 3,147,058,408.54, up from CNY 2,982,741,149.20, indicating an increase of about 5.5%[40] - Non-current assets totaled CNY 1,042,660,983.07, up from CNY 911,278,900.76, which is an increase of around 14.4%[43] - The total liabilities slightly increased to CNY 620,290,729.54 from CNY 619,553,923.59, showing a marginal growth of about 0.1%[44] - The company's equity attributable to shareholders rose to CNY 3,511,418,308.77 from CNY 3,225,001,207.85, representing an increase of approximately 8.9%[44] Cash Flow - The company’s cash flow from operating activities increased by 136.10% year-on-year, amounting to RMB 359.18 million[9] - The company reported cash inflows from operating activities of CNY 1,791,077,407.19 for the first three quarters of 2023, compared to CNY 1,729,016,599.67 in the same period of 2022, marking an increase of approximately 3.6%[48] - The net cash flow from operating activities increased to ¥359,177,957.50, compared to ¥152,130,691.78 in the previous period, reflecting a significant improvement[49] - Cash inflow from investment activities totaled ¥997,115,514.58, down from ¥1,545,309,428.47, indicating a decrease in investment returns[49] - The net cash flow from investment activities was -¥1,529,252,872.06, a decline from a positive ¥48,533,900.03 in the previous period, highlighting increased investment expenditures[49] - The total cash and cash equivalents at the end of the period decreased to ¥660,725,878.76 from ¥1,184,196,317.48, reflecting a significant drop in liquidity[49] Shareholder Information - The total number of common shareholders at the end of Q3 2023 is 10,850[21] - The largest shareholder, Shenzhen Zhongke Investment Co., Ltd., holds 42,251,300 shares, representing 22.49% of the total shares[21] - The second-largest shareholder, Nanjing Xinweichuang Enterprise Management Consulting Co., Ltd., holds 36,073,614 shares, representing 19.20% of the total shares[21] - Huakang Limited, the third-largest shareholder, holds 13,112,579 shares, representing 6.98% of the total shares[23] - The company has not disclosed any financing or margin trading activities among its top shareholders, except for Nanjing Xinweichuang, which has engaged in securities lending[22] - The company reported that the total number of shares held by the top 10 unrestricted shareholders is 42,251,300[21] - The company has not reported any significant changes in shareholder relationships or actions among the top shareholders[22] Dividend and Interest Payments - The company paid ¥103,386,880.78 in dividends and interest, slightly up from ¥100,870,018.58, indicating a stable dividend policy[49]